, Tableau 3-Effets indésirables très fréquents (++ : ? 1/10) et fréquents (+ : de ? 1/100 à < 1/10) des différentes
, Annexe 1 (suite)-Risque relatif de cancer du sein en fonction du facteur de risque-HAS 2012
, Annexe 2-Planche illustrant la production d'oestrogènes chez la femme-C.Dupuis Annexe 3-Planche illustrant le mécanismes d
, Annexe 5-Planche illustrant le mécanisme d'action des inhibiteurs de l'aromatase-C.Dupuis Annexe 6-Planche « à trous » sur le mécanisme d'action des inhibiteurs de l'aromatase
, Dupuis Annexe 7 (suite)-Cartes recto-verso des idées reçues utilisées lors de l'atelier d'ETPC.Dupuis Annexe 8 (suite)-Cartes recto-verso des effets indésirables utilisées lors de l'atelier d'ETPC.Dupuis Annexe 8 (suite)-Cartes recto-verso des effets indésirables utilisées lors de l, Annexe 7-Cartes recto-verso des idées reçues utilisées lors de l'atelier d'ETP-C
, Annexe 9-Questionnaire de satisfaction distribué aux patientes à la fin de l'atelierC
, Annexe 10-Fiche Médicament de l'ARIMIDEX® remise aux patientes à la fin de l'atelierOMEDIT Normandie
, Annexe 11-Fiche Médicament du FEMARA® remise aux patientes à la fin de l'atelierOMEDIT Normandie
, Annexe 12-Fiche Médicament de l'AROMASINE® remise aux patientes à la fin de l'atelierOMEDIT Normandie
, Annexe 13-Fiche Médicament du Tamoxifène remise aux patientes à la fin de l'atelierOMEDIT Normandie
, Annexe 15-Evaluation de l'observance d'un traitement médicamenteux (Score de Girerd)Assurance Maladie
, Annexe 16-Affiche utilisée pour communiquer auprès des patientes de l'existence d'un atelier d'éducation thérapeutique sur l
The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM, Ann Surg Oncol, vol.17, issue.6, pp.1471-1475 ,
,
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, vol.19, issue.5, pp.403-413, 1991. ,
,
Breast Cancer Screening With Imaging: Recommendations From the Society of Breast Imaging and the ACR on the Use of Mammography, Breast MRI, Breast Ultrasound, and Other Technologies for the Detection of Clinically Occult Breast Cancer, J Am Coll Radiol, vol.7, issue.1, pp.18-27 ,
Projections de l ' incidence et de la mortalité par cancer en France en, Invs, pp.1-2, 2015. ,
Estimation de l'incidence départementale des cancers en France métropolitaine, 2008. ,
, Étude à partir des données des registres des cancers du réseau Francim et des bases de données médico-administratives, vol.53, 2015.
Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers, Am J Clin Pathol, vol.123, issue.1, pp.21-28, 2005. ,
Treatment of HER2-positive breast cancer: current status and future perspectives, Nat Rev Clin Oncol, vol.9, issue.1, pp.16-32, 2011. ,
Dépistage du cancer du sein en France : identification des femmes à haut risque et modalités de dépistage Volet 1. Recommandations de santé publique, 2012. ,
,
Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012. Inst Veill Sanit, vol.122, 2013. ,
, Principales recommandations de prise en charge des femmes porteuses d'une mutation de BRCA1 ou BRCA2, 2009.
Aluminium chloride promotes tumorigenesis and metastasis in normal murine mammary gland epithelial cells, Int J Cancer, vol.139, issue.12, pp.2781-90, 2016. ,
Red Clover, and Isoflavones and Breast Cancer: A Systematic Review. Shioda T, éditeur. PLoS One, vol.8, 2013. ,
Cardiac glycosides and breast cancer risk: A systematic review and meta-analysis of observational studies, Int J cancer [Internet]. 1 mars, vol.140, issue.5, pp.1035-1076, 2017. ,
Smoking and survival after breast cancer diagnosis: a prospective observational study and systematic review, Breast Cancer Res Treat, vol.136, issue.2, pp.521-554, 2012. ,
Smoking and mortality in women diagnosed with breast cancer-a systematic review with meta-analysis based on 400,944 breast cancer cases. Gland Surg, vol.6, pp.385-93, 2017. ,
Vitamin D supplementation decreases serum 27-hydroxycholesterol in a pilot breast cancer trial ,
, Breast Cancer Res Treat, issue.7, p.12, 2017.
,
Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis, p.12, 2014. ,
,
Physical Activity and Weight Loss Reduce the Risk of Breast Cancer: A Meta-analysis of 139 Prospective and Retrospective Studies, Clin Breast Cancer, issue.17, 2017. ,
,
Physical Activity and Survival After Breast Cancer Diagnosis, JAMA, vol.25, issue.2005, p.2479 ,
Monographie du NOLVADEX (Tamoxifène) 20 mg cp ,
Monographie du FASLODEX (Fulvestrant) 250 mg sol inj-Synthèse ,
Monographie du FARESTON (Torémifène) 60 mg cp ,
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment, J Natl Cancer Inst, vol.97, issue.1, pp.30-39, 2005. ,
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials, 27 août, vol.378, issue.9793, pp.771-84, 2011. ,
Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective, Am J Surg, vol.192, issue.4, pp.496-504, 2006. ,
Monographie de l'AROMASINE (Exemestane) 25 mg cp enr, p.25 ,
Monographie de l'ARIMIDEX (anastrozole) 1 mg cp pellic ,
Monographie du FEMARA (létrozole) 2,5 mg cp pellic ,
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial, Lancet Oncol [Internet], vol.11, issue.12, pp.70257-70263, 2010. ,
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up, Lancet Oncol, vol.12, issue.12, pp.1101-1109, 2011. ,
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study, J Clin Oncol [Internet]. 1 mars, vol.30, issue.7, pp.709-726, 2012. ,
Monographie de l'ENANTONE (Leuproréline) LP 3,75 mg pdre/solv p susp inj LP IM/SC ,
,
Goséréline) 3,6 mg implant inj en seringue préremplie SC ,
,
, Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. Cochrane database Syst Rev
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years, N Engl J Med, vol.377, issue.9, pp.1836-1882, 2017. ,
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial, Lancet, vol.381, issue.9, pp.805-821, 2013. ,
,
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review, Cancer Treat Rev [Internet]. avr, vol.34, issue.2, pp.157-74, 2008. ,
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years, N Engl J Med, vol.375, issue.3, pp.209-228, 2016. ,
Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis. Breast Cancer, 2018. ,
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis. Med (United States, vol.96, pp.1-6, 2017. ,
Effect of tamoxifen on serum cholesterol and lipoproteins during chemohormonal therapy, Clin Chim Acta, vol.31, issue.1993, pp.43-52 ,
Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy, R35. Disponible sur, vol.16 ,
, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, vol.365, issue.9472, pp.1687-717, 2005.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial, Lancet, vol.381, issue.9, pp.805-821, 2013. ,
,
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials, Lancet, vol.378, issue.9793, pp.771-84 ,
Therapeutic Patient Education ,
, Education for Health: Change in Learning & Practice, vol.13, 2000.
, 879 du 21 juillet 2009 portant réforme de l'hôpital et relative aux patients, à la santé et aux territoires Titre 3 article, p.84, 2009.
,
, Décret n° 2010-906 du 2 août 2010 relatif aux compétences requises pour dispenser l'éducation thérapeutique du patient
, UNICANCER-Etude prospective-La cancérologie en 2025 : un patient et des soins connectés
,
Plan cancer, 2014. ,
, World Health Organization. Adherence to long-term therapies : Evidence for action
, , 2003.
,
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review, Breast Cancer Res Treat, vol.12, issue.2012, pp.459-78 ,
A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians, Breast Cancer Res Treat [Internet], vol.12, issue.2013, pp.325-333 ,
Adherence to endocrine therapy in breast cancer adjuvant and prevention settings, Cancer Prev Res, vol.1, issue.2014, pp.378-87 ,
Symptoms associated with tamoxifen treatment in postmenopausal women, Arch Intern Med, vol.151, issue.9, pp.1842-1849, 1991. ,
Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients, J Clin Oncol, vol.28, issue.20, pp.4120-4128, 2010. ,
Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials, pp.13-93 ,
, Breast Cancer Res Treat, vol.142, issue.7, pp.455-464, 2013.
Vivre sous hormonothérapie après un cancer du sein : Les enjeux de l'éducation thérapeutique des patientes. Poitiers : Faculté de Médecine et de Pharmacie, 2013. ,
Assessment of antihypertensive compliance using a self-administered questionnaire: development and use in a hypertension clinic, Presse Med, vol.30, issue.21, pp.1044-1052 ,
, , 2017.
,
Randomised, double-blind, placebo-controlled trials of non-individualised homeopathic treatment: systematic review and meta-analysis, vol.6, p.63 ,
Randomised placebo-controlled trials of individualised homeopathic treatment: systematic review and meta-analysis, vol.3, p.142 ,
Définition de la naturopathie, Larousse médical. Larousse, 2012. ,
Grille d'aide à l'évaluation de la demande d'autorisation par l'ARS ,
Predictive validity of a medication adherence measure in an outpatient setting, J Clin Hypertens ,